Analyst Daniel Brennan from TD Cowen reiterated a Buy rating on Guardant Health and increased the price target to $100.00 from $72.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daniel Brennan has given his Buy rating due to a combination of factors that highlight Guardant Health’s strong performance and potential for future growth. The company delivered impressive third-quarter results, with a 34% year-over-year increase in sales, surpassing consensus expectations. Notably, the G360 volume growth accelerated for the fifth consecutive quarter, and Shield revenues significantly exceeded market predictions, indicating robust demand and effective execution.
Furthermore, Guardant Health’s gross margins were ahead of expectations, and the company achieved positive free cash flow outside of its Shield business for the first time. The raised guidance for 2025, along with the company’s expanding margins and favorable top-line growth setup, reinforces the positive outlook. Brennan’s increased price target to $100 reflects the strong momentum and multiple upside levers that remain for Guardant Health, making it a compelling investment opportunity.
In another report released on October 28, William Blair also maintained a Buy rating on the stock with a $0.00 price target.
Based on the recent corporate insider activity of 170 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GH in relation to earlier this year.